Alto Neuroscience, Inc. (ANRO)

USD 3.64

(-3.96%)

Long Term Debt Summary of Alto Neuroscience, Inc.

  • Alto Neuroscience, Inc.'s latest annual long term debt in 2023 was 151.33 Million USD , up 85.24% from previous year.
  • Alto Neuroscience, Inc.'s latest quarterly long term debt in 2024 Q2 was 7.74 Million USD , down -12.15% from previous quarter.
  • Alto Neuroscience, Inc. reported annual long term debt of 81.7 Million USD in 2022, up 114.08% from previous year.
  • Alto Neuroscience, Inc. reported annual long term debt of 38.16 Million USD in 2021, down 0.0% from previous year.
  • Alto Neuroscience, Inc. reported quarterly long term debt of 8.81 Million USD for 2024 Q1, down -94.18% from previous quarter.
  • Alto Neuroscience, Inc. reported quarterly long term debt of 151.33 Million USD for 2023 Q4, up 1451.39% from previous quarter.

Annual Long Term Debt Chart of Alto Neuroscience, Inc. (2023 - 2021)

Historical Annual Long Term Debt of Alto Neuroscience, Inc. (2023 - 2021)

Year Long Term Debt Long Term Debt Growth
2023 151.33 Million USD 85.24%
2022 81.7 Million USD 114.08%
2021 38.16 Million USD 0.0%

Peer Long Term Debt Comparison of Alto Neuroscience, Inc.

Name Long Term Debt Long Term Debt Difference
ADC Therapeutics SA 112.73 Million USD -34.248%
Annovis Bio, Inc. - USD -Infinity%
Biohaven Pharmaceutical Holding Company Ltd. 27.56 Million USD -448.943%
Ginkgo Bioworks Holdings, Inc. 221.83 Million USD 31.779%
Nuvation Bio Inc. 2.03 Million USD -7336.757%
Nuvation Bio Inc. 2.03 Million USD -7336.757%
Arcus Biosciences, Inc. 110 Million USD -37.58%
Theriva Biologics, Inc. 162 Thousand USD -93318.519%
Zymeworks Inc. 22.46 Million USD -573.781%